• LeonaBio appointed Fred Callori, Natalie Holles, Peter B. Silverman to board, effective May 5, 2026.
• Callori is partner and managing director at Perceptive Advisors, previously held senior corporate development roles at life sciences accelerator Xontogeny.
• Holles is CEO of Aura Biosciences, previously led Third Harmonic Bio, previously held senior operating and corporate development roles at Audentes Therapeutics, Hyperion Therapeutics, Immune Design.
• Silverman previously served as COO of Merus until its acquisition by Genmab in December 2025, previously was Merus general counsel, earlier was partner at Kirkland & Ellis.
• John Fluke Jr. retired from board effective May 4, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LeonaBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070920PRIMZONEFULLFEED9715519) on May 07, 2026, and is solely responsible for the information contained therein.